Skeletal implications and management of cystinosis: three case reports and literature review
- 17 August 2016
- journal article
- review article
- Published by Portico in BoneKEy Reports
- Vol. 5, 828
- https://doi.org/10.1038/bonekey.2016.55
Abstract
Hypophosphatemic rickets and short stature are observed in nephropathic cystinosis, an orphan autosomal recessive lysosomal storage disease due to a deficiency of cystinosin (CTNS gene). Although bone impairment is not common, it nevertheless appears to be more and more discussed by experts, even though the exact underlying pathophysiology is unclear. Four hypotheses are currently discussed to explain such impairment: copper deficiency, bone consequences of severe hypophosphatemic rickets during infancy, cysteamine toxicity and abnormal thyroid metabolism. In murine models, the invalidation of the CTNS gene is associated neither with renal phosphate wasting nor with renal failure, but causes severe osteopenia and growth retardation, thus raising the hypothesis of a specific underlying bone defect in cystinosis. Moreover, the in vitro ability of mesenchymal stromal cells isolated from bone marrow to differentiate along the osteoblastic lineage is reduced in patients with cystinosis as compared with cells obtained from healthy controls, this cellular abnormality being reverted after cysteamine treatment. From our experience of three pediatric patients with cystinosis and severe bone deformations having undergone a thorough biochemical evaluation, as well as a bone biopsy, we conclude that even though copper deficiency, high-doses cysteamine regimens and abnormal thyroid metabolism may worsen the bone picture in cystinosis patients, the exact pathophysiology of such impairment remains to be defined. The role of chronic hypoparathyroidism due to chronic phosphate wasting could also be discussed. In the future, larger and prospective studies should focus on this topic because of the potential major impact on patients' quality of life.Keywords
This publication has 14 references indexed in Scilit:
- Cysteamine treatment restores the in vitro ability to differentiate along the osteoblastic lineage of mesenchymal stromal cells isolated from bone marrow of a cystinotic patientJournal of Translational Medicine, 2015
- Nephropathic cystinosis: an international consensus documentNephrology Dialysis Transplantation, 2014
- Nephropathic Cystinosis — A Gap between Developing and Developed NationsThe New England Journal of Medicine, 2014
- Cystinosis with Sclerotic Bone LesionsJIMD Reports, 2013
- Progressive destructive bone changes in patients with cystinosisSkeletal Radiology, 2013
- Cystinosis: the evolution of a treatable diseasePediatric Nephrology, 2012
- A co‐occurrence of osteogenesis imperfecta type VI and cystinosisAmerican Journal of Medical Genetics Part A, 2012
- Intralysosomal Cystine Accumulation in Mice Lacking Cystinosin, the Protein Defective in CystinosisMolecular and Cellular Biology, 2002
- Clinical polymorphism of cystinosis encephalopathy. Results of treatment with cysteamineJournal of Inherited Metabolic Disease, 1995
- Improved Renal Function in Children with Cystinosis Treated with CysteamineThe New England Journal of Medicine, 1993